Complement C1s activation in degenerating articular cartilage of rheumatoid arthritis patients: Immunohistochemical studies with an active form specific antibody

Annals of the Rheumatic Diseases

Volumn 58, Issue 3, 1999, Pages 175-181

  Nakagawa, Koichi ^a   Sakiyama, Hisako ^b   Tsuchida, Toyomitsu ^a   Yamaguchi, Kiichiro ^a   Toyoguchi, Toru ^b   Masuda, Riako ^a   Moriya, Hideshige ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1;

ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ARTICLE; ARTICULAR CARTILAGE; AUTOIMMUNITY; CARTILAGE DEGENERATION; CARTILAGE MATRIX; COLLAGEN DEGRADATION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RHEUMATOID ARTHRITIS;

EID: 0032910535     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.3.175     Document Type: Article

References (46)

1. Andriopoulos NA, Mestecky J, Miller EJ, Bradley EL. Antibodies to human native and denatured collagens in synovia! fluids of patients with rheumatoid arthritis. Clin Immunol Immunopathol 1976;6:209-12.
2. Jasin HE. Autoantibody specificities in immune complexes sequestered in articular cartilage of patients \vith rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1985;28: 241-8.
3. Menzel J, Steffen C, Kolarz G, Eberl R, Frank O, Thumb N. Demonstration of antibodies to collagen and of collagen-anticollagen immune complexes in synovial fluids. Ann Rheum Dis 1976;35:446-50.
4. Clague RB, Moore LJ. IgG and IgM antibody to native type II collagen in rheumatoid arthritis serum and synovial fluid. Arthritis Rheum 1984;27:1370-7.
5. Kresina TF, Yoo JU, Goldberg V. Evidence that a humoral immune response to autologous cartilage proteoglycan can participate in the induction of cartilage pathology. Arthritis Rheum 1988;31:248-57.
6. Mollenhauer J, von der Alark K, Burmester G, Glucker K, Lutjen-Drecoll E, Brune K. Serum antibodies against chondrocyte cell surface proteins in osteoarthritis and rheumatoid arthritis. J Rheumatol 1988; 15:1811-17.
7. Dayer JM, Passwell JH, Schneeberger EE, Krane SM. Interactions among rheumatoid synovial cells and monocyte-macrophages: production of collagenase-stimulating factor by human monocytes exposed to concanavalin A or immunoglobulin Fc fragments. J Immunol 1980; 124:1712-20.
8. Cooke D, Saura R, Uno K, Scudamore A. Interactions of immunoglobulins and chondrocytes. J Rheumatol Suppl 1991;27:114-16.
9. Saura R, Uno K, Satsuma S, Kurz EU, Scudamore RA Cooke TD. Mechanisms of cartilage degradation in inflammatory arthritis: interaction between chondrocytes and immunoglobulin G.J Rheumatol 1993;20:336-43.
10. Takagi T, Jasin HE. Interactions of synovia! fluid immunoglobulins with chondrocytes. Arthritis Rheum 1992;35: 1502-9.
11. Cooke TDV, Kurd ER, Jasin HE, Bienenstock J, Ziff M. Identification of immunoglobulins and complement in rheumatoid articular collagenous tissues. Arthritis Rheum 1975;18:541-51.
12. Cooke TDV, Scudamore RA. Studies in the pathogenesis of rheumatoid arthritis. 2: Antigea'antibody reactions with avascular joint tissues. Er J Rheumatol 1989;28:333-10.
13. Vetto AA, Mannik M, Zatarain-Rios E, \Vener MH. Immune deposits in articular cartilage of patients with rheumatoid arthritis have a granular pattern not seen in osteoarthritis. Rheumatol Int I990;10:13-19.
14. Gulati P, Lemercier C, Guc D, Lappin D, \Vhaley K. Regulation of the synthesis of Cl subcomponents and Cl-inhibitor. Behring Inst Mitt 1993;93:196-203.
15. Bradley K, North J, Saunders D, Schwaeble \V, Jeziorskà M, VCbolley DE, et al. Synthesis of classical pathway complement components by chondrocytes. Immunology-1996;88: 648-56.
16. Menai D, Brune K, Mollenhauer J. Cytotoxic effects of rheumatoid arthritis sera on chondrocytes. Biochim BiophysActa 1992;! 138:85-92.
17. Satsuma S, Scudamore RA, Cooke TDV, Aston \VP, Saura R. Toxicity of complement for chondrocytes. A possible sourse of cartilage degradation in inflammatory arthritis. Rheumatol Int 1993;13:71-5.
18. Sakij-ama H, Nishino Y, Tanaka T, Tomosawa T, Kinoshita H, Nagata K, et al. Purification and charactarization of a novel calcium-dependent serine proteinase secreted from malignant hamster embryo fibroblast NH2C2. Biochim BiophysActa 1989;990:156-61.
19. Yamaguchi K, Sakiyama H, Alatsumoto Al, Moriya H, Sakiyama S. Degradation of type I and type II collagen by human Cls. FEES Lett 1990;268:206-8.
20. Sakiyama H, Nakagawa K, Kuriiwa K, Imai K, Okada Y, Tsuchida T, et al. Complement Cls, a classical enzyme with novel functions at endochondral ossification center: immunohistochemical staining of activated C l s \vith a neoantigen specific antibody. Cell Tissue Res 1997;288:557-65.
21. Sakiyama H, Inaba N, Toyoguchi T, Okada Y, Matsumoto A I, Moriya H, et al. Immunolocalization of complement Cls and matrix metalloproteinase 9 (92 kDa gelatinase/ type IV collagenase) in the primary ossification center of the human femur. Cell Tissue Res 1994;277:239-45.
22. Toyoguchi T, Yamaguchi K, Nakagawa K, Fukazawa T, Aioriya H, Sakiyama H. Change of complement Cls synthesis during development of hamster cartilage. Cell Tissue Res 1996;285:199-204.
23. Okada Y, Shinmei AI, Tanaka O, Naka K, Kimura A, Nakanishi I, et al. Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab Invest 1992;66:680-90.
24. Alohtai Al, Smith RL, Schurman DJ, Tsuji Y, Torti FAI, Hutchinson NI, et ai. Expression of 92-kD type IV collagenase / gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. J Clin Invest 1993;92:179-85.
25. Singer II, Kawka D\V, Bayne EK, Donatelli SA, \VeidnerJR, Williams HR, ei al. VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis. J Clin Invest 1995;95:2178-86.
26. Arnett FC, Edworthy SAl, Bloch DA, AlcShane DJ, Fries JF, Cooper NS, ei al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988:31:315-24.
27. Alatsumoto AI, Nagaki K. Functional analysis of activated Cls, a subcomponent of human complement, by monoclonal antibodies. J Immunol 1986;137:2907-I2.
28. Nakagawa K, Sakiyama H, Fukazawa T, Alatsumoto M, Takigawa Al, Toyoguchi T, et ai. Coordinated change between complement Cls production and chondrocyte differentiation in vitro. Cell Tissue Res 1997;289:299-305.
29. Sakiyama H, Yamaguchi K, Chiba K, Nagata K, Taniyama C, Alatsumoto Al, al. Biochemical characterization and tissue distribution of hamster complement C l s. J Immunol 1991;146:183-7.
30. Gigli I, Porter RR, Sim RB. The unactivated form of the first component of human complement, Cl. Biochem J 1976;157:541-8.
31. Haper E. Collagenases. Annu Rev Biochem 1980;49:1063-78.
32. Gilman SC. Activation of rabbit articular chondrocytes by recombinant human cytokines. J Rheumatol 1987;14: 1002-7.
33. Schnyder J, Payne T, Dinarello CA. Human monocyte or recombinant interleukin l 's are specific for the secretion of a metalloproteinase from chondrocytes. J Immunol 1987; 138:496-503.
34. Shingu Aï, Nagai Y, Isayama T, Naono T, Nobunaga Ai, Nagai Y. The effects of cytokines on metalloproteinase inhibitors (TIAIP) and collagenase production by human chondrocytes and TIAIP production by synovial cells and endothelial cells. Clin Exp Immunol 1993;94:145-9.
35. Katz Y, Strunk RC. Synthesis and regulation of Cl inhibitor in human skin fibroblasts. J Immunol 1989; 142:2041-5.
36. Terato K, Hasty KA, Cremer AIA, Stuart JM, Townes AS, Rang AH. Collagen-induced arthritis in mice. Localization of an arthritogenic determinant to a fragment of the type II collagen molecule. J Exp Aled 1985;162:637-46.
37. \Vatson \VC, Thompson JP, Terato K, Cremer AIA, Kang AH. Human HLA-DR beta gene hypervariable region homolog}' in the biobreeding BB rat: selection of the diabetic-resistant subline as a rheumatoid arthritis research tool to characterize the immunopathologic response to human type II collagen. J Exp Aled 1990;172:I331-9.
38. Cremer AIA, Terato K, Viatson \VC, Griffiths MM, Townes AS, Kang AH. Collagen-induced arthritis in rats. Examination of the epitope specificities of circulating and cartilagebound antibodies produced by outbred and inbred rats using cyanogen bromide-derived peptides purified from heterologous and homologous type II collagens. J Immunol 1992;149:1045-53.
39. Terato K, Harper DS, Griffiths MM, Hasty DL, Ye XJ, Cremer AIA, ct al. Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity 1995; 22:137-47.
40. Alyers LK, Terato K, Sever JM, Stuart JM, Kang AH. Characterization of a tolerogenic T cell epitope of type II collagen and its relevance to collagen induced arthritis. J Immunol 1992;149:1439-43.
41. Myers LK, Seyer JM, Smart JM, Terato K, David CS, Kang AH. T cell epitppes of type II collagen that regulate murine collagen-induced arthritis. ] Immunol 1993;151: 500-5.
42. Brand DD, Myers LK, Terato K, \X"hittington KB, Stuart JM, Kang AH, et al. Characterization of the T cell determinants in the induction of autoimmune arthritis by bovine alpha 1(II)-CB11 in H-2q mice. J Immunol 1994;152: 3088-97.
43. Ochi T, Yonemasu K, Iwase R, Sasaki T, Tsuyama K, Ono K. Serum Clq levels as a prognostic guide to articular ero-sions in patients with rheumatoid arthritis. Arthritis Rheum 1984;27:883-7.
44. Ochi T, Iwase R, Yonemasu K, Matsukawa M, Yoneda M, Yukioka M, et al. Natural course of joint destruction and fluctuation of serum Clq levels in patients with rheumatoid arthritis. Arthritis Rheum 1988;31:37-13.
45. Olsen NJ, Ho E, Barats L. Clinical correlations with serum Clq levels in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:187-91.
46. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic evaluation of rheumatoid arthritis. JAMA 1949;140:659-62.